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Summary
Background Trial ﬁ ndings show cognitive behaviour therapy (CBT) and graded exercise therapy (GET) can be eﬀ ective 
treatments for chronic fatigue syndrome, but patients’ organisations have reported that these treatments can be harmful 
and favour pacing and specialist health care. We aimed to assess eﬀ ectiveness and safety of all four treatments.
Methods In our parallel-group randomised trial, patients meeting Oxford criteria for chronic fatigue syndrome were 
recruited from six secondary-care clinics in the UK and randomly allocated by computer-generated sequence to receive 
specialist medical care (SMC) alone or with adaptive pacing therapy (APT), CBT, or GET. Primary outcomes were fatigue 
(measured by Chalder fatigue questionnaire score) and physical function (measured by short form-36 subscale score) up 
to 52 weeks after randomisation, and safety was assessed primarily by recording all serious adverse events, including 
serious adverse reactions to trial treatments. Primary outcomes were rated by participants, who were necessarily 
unmasked to treatment assignment; the statistician was masked to treatment assignment for the analysis of primary 
outcomes. We used longitudinal regression models to compare SMC alone with other treatments, APT with CBT, and 
APT with GET. The ﬁ nal analysis included all participants for whom we had data for primary outcomes. This trial is 
registered at http://isrctn.org, number ISRCTN54285094.
Findings We recruited 641 eligible patients, of whom 160 were assigned to the APT group, 161 to the CBT group, 160 to 
the GET group, and 160 to the SMC-alone group. Compared with SMC alone, mean fatigue scores at 52 weeks were 
3·4 (95% CI 1·8 to 5·0) points lower for CBT (p=0·0001) and 3·2 (1·7 to 4·8) points lower for GET (p=0·0003), but did 
not diﬀ er for APT (0·7 [–0·9 to 2·3] points lower; p=0·38). Compared with SMC alone, mean physical function scores 
were 7·1 (2·0 to 12·1) points higher for CBT (p=0·0068) and 9·4 (4·4 to 14·4) points higher for GET (p=0·0005), but 
did not diﬀ er for APT (3·4 [–1·6 to 8·4] points lower; p=0·18). Compared with APT, CBT and GET were associated with 
less fatigue (CBT p=0·0027; GET p=0·0059) and better physical function (CBT p=0·0002; GET p<0·0001). Subgroup 
analysis of 427 participants meeting international criteria for chronic fatigue syndrome and 329 participants meeting 
London criteria for myalgic encephalomyelitis yielded equivalent results. Serious adverse reactions were recorded in 
two (1%) of 159 participants in the APT group, three (2%) of 161 in the CBT group, two (1%) of 160 in the GET group, 
and two (1%) of 160 in the SMC-alone group.
Interpretation CBT and GET can safely be added to SMC to moderately improve outcomes for chronic fatigue 
syndrome, but APT is not an eﬀ ective addition.
Funding UK Medical Research Council, Department of Health for England, Scottish Chief Scientist Oﬃ  ce, Department 
for Work and Pensions.
Introduction
Chronic fatigue syndrome is characterised by chronic 
disabling fatigue in the absence of an alternative 
diagnosis.1 Myalgic encephalomyelitis is thought by some 
researchers to be the same disorder and by others as 
diﬀ erent with separate diagnostic criteria.1,2 The 
prevalence of chronic fatigue syndrome is between 0·2% 
and 2·6% worldwide, dependent on the deﬁ nition used.1 
Prognosis is poor if untreated.3
Speciﬁ c therapies can improve outcomes. The UK 
National Institute for Health and Clinical Excellence 
(NICE) recommend cognitive behaviour therapy (CBT) 
and graded exercise therapy (GET).2 Although this 
recommendation was supported by systematic reviews,4–7 
supporting evidence remains restricted to small trials.4–7 
Surveys by patients’ organisations in the UK have 
reported that CBT and GET are sometimes harmful, and 
have recommended pacing and specialist health care.8,9
We designed the pacing, graded activity, and cognitive 
behaviour therapy: a randomised evaluation (PACE) 
trial10 to compare pacing, deﬁ ned as adaptive pacing 
therapy (APT), CBT, and GET, when added to specialist 
medical care (SMC) with SMC alone. We sought evidence 
of beneﬁ t and harm. We also aimed to compare APT 
against CBT and GET and examine these comparisons in 
subgroups satisfying diﬀ erent diagnostic criteria for 
chronic fatigue syndrome and myalgic encephalomyelitis. 
We postulated that CBT and GET would be more eﬀ ective 
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than would APT and SMC, and that APT would be more 
eﬀ ective than SMC alone.
Methods
Study design and participants
PACE was a parallel, four group, multicentre, randomised 
trial, with outcomes assessed up to 52 weeks after 
randomisation for patients with chronic fatigue 
syndrome.10 We recruited 641 participants from consecutive 
new out patients attending six specialist chronic fatigue 
syndrome clinics in the UK National Health Service 
between March 18, 2005, and Nov 28, 2008, and completed 
outcome data collection in January, 2010.
Several diagnostic criteria exist for chronic fatigue 
syndrome and myalgic encephalomyelitis.11–13 We selected 
participants in accordance with Oxford criteria for chronic 
fatigue syndrome.11 These criteria require fatigue to be the 
main symptom, accompanied by signiﬁ cant disability, in 
the absence of an exclusionary medical or psychiatric 
diagnosis (psychosis, bipolar disorder, substance misuse, 
an organic brain disorder, or an eating disorder).11 All 
participants were medically assessed by the specialist clinic 
doctors to exclude alternative diagnoses.2,12 Research 
assessors used the structured clinical interview from the 
Diagnostic and Statistical Manual of Mental Disorders IV 
to diagnose exclusionary and comorbid psychiatric 
disorders (ie, mood and anxiety disorders).10,14 
Other eligibility criteria consisted of a bimodal score 
of 6 of 11 or more on the Chalder fatigue questionnaire15 
and a score of 60 of 100 or less on the short form-36 
physical function subscale.16 11 months after the trial 
began, this requirement was changed from a score of 60 
to a score of 65 to increase recruitment.
We excluded patients who were younger than 18 years or 
at signiﬁ cant risk of self-harm, unable to attend hospital 
appointments, unable to speak and read English, had 
medical needs that made participation inappropriate, had 
previously received a trial treatment for their present 
illness at a PACE trial clinic (we initially excluded anyone 
who had received a trial treatment, but found the nature of 
treatment given elsewhere hard to establish).10 Participants 
were also assessed by international criteria for chronic 
fatigue syndrome,12 requiring four or more accompanying 
symptoms, and the London criteria13 for myalgic 
encephalomyelitis (version 2), requiring postexertional 
fatigue, poor memory and concentration, symptoms that 
ﬂ uctuate, and no primary depressive or anxiety disorder 
(interpreted as an absence of any such disorder).
We obtained separate written informed consent for 
assessment and entry into the trial. The West Midlands 
Multicentre Research Ethics Committee (MREC 02/7/89) 
approved the study.
Randomisation and masking
Participants were allocated to treatment groups through 
the Mental Health and Neuroscience Clinical Trials Unit 
(London, UK), after baseline assessment and obtainment 
of consent. A database programmer undertook treatment 
allocation, independently of the trial team. The ﬁ rst three 
participants at each of the six clinics were allocated with 
straightforward randomisation. Thereafter allocation was 
stratiﬁ ed by centre, alternative criteria for chronic fatigue 
syndrome12 and myalgic encephalomyelitis,13 and 
depressive disorder (major or minor depressive episode or 
dysthymia),14 with computer-generated probabilistic 
minimisation. Once notiﬁ ed of treatment allocation by the 
Clinical Trials Unit, the research assessor informed the 
participant and clinicians. One therapist was available for 
every therapy per centre, with few exceptions. Specialist 
medical care doctors were allocated by convenience. As 
with any therapy trial, participants, therapists, and doctors 
could not be masked to treatment allocation and it was 
also impractical to mask research assessors. The primary 
outcomes were rated by participants themselves. The 
statistician undertaking the analysis of primary outcomes 
was masked to treatment allocation.
Procedures
Panel 1 shows treatment strategies and webappendix p 1 
shows characteristics of treating clinicians. Therapy 
leaders (one per therapy and with substantial experience 
in treatment of chronic fatigue syndrome) trained 
therapists until they were deemed competent to provide 
trial treatments. Individual therapy supervision was 
provided once every month, and by group every 
3 months.24 All treatment sessions were recorded 
acoustically. Two independent clinicians, who were 
masked to allocated treatment, rated recordings of a 
randomly chosen sample of the tenth (or nearest) session 
of 62 (13%) of 480 participants (two sessions for every 
therapist, when available) for therapy type, adherence to 
the manual (7-point Likert scale), and therapeutic alliance 
between therapist and participant (7-point Likert scale). 
These clinicians recorded when masking had failed, such 
as when the treatment was mentioned by name. All 
doctors received training in specialist medical care, and 
we assessed competence and monitored manual 
adherence for most. We deﬁ ned ten sessions of therapy 
or three sessions of specialist medical care alone as 
adequate treatment for the per-protocol analysis. We 
recorded number of treatment sessions attended, active 
withdrawals from treatment, additional treatments 
received, and dropouts from follow-up.
We undertook assessments at baseline and 12 weeks 
(mid-therapy), 24 weeks (post-therapy), and 52 weeks 
after randomisation. Primary outcomes were also 
assessed at the time of dropouts, and used when no 
other outcome data were available. The research 
assessors did the assessments, usually face-to-face in 
clinic. Most measures were self-rated by the participant. 
Because masking of research assessors to treatment 
allocation after randomisation was impractical, we 
relied on participant ratings to keep observer bias to 
a minimum.
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Outcomes
The two participant-rated primary outcome measures 
were the Chalder fatigue questionnaire (Likert scoring 0, 
1, 2, 3; range 0–33; lowest score is least fatigue)15 and the 
short form-36 physical function subscale (version 2; range 
0–100; highest score is best function).16 Before outcome 
data were examined, we changed the original bimodal 
scoring of the Chalder fatigue questionnaire (range 0–11) 
Overview
We standardised treatments by provision of manuals for 
doctors, therapists, and participants. At least three sessions 
of specialist medical care were offered to participants during 
the 12 months, and more were offered if clinically indicated. 
Up to 14 therapy sessions were offered during the first 
23 weeks; the first four were once a week and subsequently 
they were once every 2 weeks. An additional booster session 
was offered at 36 weeks. No other additional sessions were 
offered. Most treatments were delivered face-to-face but 
some were provided by telephone. Treatment was provided 
individually although participants could be accompanied if 
they wanted.
Specialist medical care (SMC)
SMC was provided by doctors with specialist experience in 
chronic fatigue syndrome (webappendix p 1). All participants 
were given a leaﬂ et explaining the illness and the nature of 
this treatment. The manual was consistent with good medical 
practice, as presently recommended.2 Treatment consisted of  
an explanation of chronic fatigue syndrome, generic advice, 
such as to avoid extremes of activity and rest, speciﬁ c 
advice on self-help, according to the particular approach 
chosen by the participant (if receiving SMC alone), and 
symptomatic pharmacotherapy (especially for insomnia, 
pain, and mood).
Adaptive pacing therapy (APT)
APT was based on the envelope theory of chronic fatigue 
syndrome.17,18 This theory regards chronic fatigue syndrome as 
an organic disease process that is not reversible by changes in 
behaviour and which results in a reduced and ﬁ nite amount 
(envelope) of available energy. The aim of therapy was to 
achieve optimum adaptation to the illness, hence APT. This 
adaptation was achieved by helping the participant to plan and 
pace activity to reduce or avoid fatigue, achieve prioritised 
activities and provide the best conditions for natural 
recovery.13,17,18 Therapeutic strategies consisted of identifying 
links between activity and fatigue by use of a daily diary, with 
corresponding encouragement to plan activity to avoid 
exacerbations, developing awareness of early warnings of 
exacerbation, limiting demands and stress, regularly planning 
rest and relaxation, and alternating diﬀ erent types of activities, 
with advice not to undertake activities that demanded more 
than 70% of participants’ perceived energy envelopes. 
Increased activities were encouraged, if the participant felt 
able, and as long as they did not exacerbate symptoms.
Because this treatment had not been described in a manual, we 
created and piloted manuals for therapists and patients on the 
basis of previous descriptions,13,17 what pilot patients and 
clinicians reported as helpful, and with the advice of 
experienced therapists. Westcare and Action for ME helped in 
the design of the therapy and endorsed the ﬁ nal manuals.18 APT 
was provided by occupational therapists (webappendix p 1).
Cognitive behaviour therapy (CBT)
CBT was done on the basis of the fear avoidance theory of 
chronic fatigue syndrome. This theory regards chronic fatigue 
syndrome as being reversible and that cognitive responses 
(fear of engaging in activity) and behavioural responses 
(avoidance of activity) are linked and interact with 
physiological processes to perpetuate fatigue. The aim of 
treatment was to change the behavioural and cognitive 
factors assumed to be responsible for perpetuation of the 
participant’s symptoms and disability. Therapeutic strategies 
guided participants to address unhelpful cognitions, 
including fears about symptoms or activity by testing them in 
behavioural experiments. These experiments consisted of 
establishing a baseline of activity and rest and a regular sleep 
pattern, and then making collaboratively planned gradual 
increases in both physical and mental activity. Furthermore, 
participants were helped to address social and emotional 
obstacles to improvement through problem-solving. Therapy 
manuals were based on manuals used in previous trials.19–21 
CBT was delivered mainly by clinical psychologists and nurse 
therapists (webappendix p 1).
Graded exercise therapy (GET)
GET was done on the basis of deconditioning and exercise 
intolerance theories of chronic fatigue syndrome. These 
theories assume that the syndrome is perpetuated by 
reversible physiological changes of deconditioning and 
avoidance of activity. These changes result in the 
deconditioning being maintained and an increased 
perception of eﬀ ort, leading to further inactivity. The aim of 
treatment was to help the participant gradually return to 
appropriate physical activities, reverse the deconditioning, 
and thereby reduce fatigue and disability. Therapeutic 
strategies consisted of establishment of a baseline of 
achievable exercise or physical activity, followed by a 
negotiated, incremental increase in the duration of time 
spent physically active. Target heart rate ranges were set 
when necessary to avoid overexertion, which eventually 
aimed at 30 min of light exercise ﬁ ve times a week. When this 
rate was achieved, the intensity and aerobic nature of the 
exercise was gradually increased, with participant feedback 
and mutual planning. The most commonly chosen exercise 
was walking. The therapy manual was based on that used in 
previous trials.22,23 GET was delivered by physiotherapists and 
one exercise physiologist (webappendix p 1).
Panel 1: Treatments provided
For the treatment manuals and 
the leaﬂ et given to participants 
see http://www.pacetrial.org/
trialinfo.html
For more on Action for ME see 
http://www.afme.org.uk
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3158 screened for eligibility
898 assessed for eligibility by 
research assessor at baseline
641 randomly allocated to
treatment groups
160 assigned to receive APT
1 not treated
143 adequately treated
15 inadequately treated
12 weeks
0 lost to follow-up
1 withdrew
24 weeks
0 lost to follow-up
8 withdrew
52 weeks
6 lost to follow-up
2 withdrew
159 analysed 155 analysed 159 analysed 157 analysed
1 excluded 
due to late 
withdrawal 
of consent
6 excluded 1 excluded 3 excluded
12 weeks
6 lost to follow-up
6 withdrew
24 weeks
5 lost to follow-up
10 withdrew
52 weeks
2 lost to follow-up
1 withdrew
12 weeks
1 lost to follow-up
2 withdrew
24 weeks
1 lost to follow-up
5 withdrew
52 weeks
4 lost to follow-up
3 withdrew
12 weeks
3 lost to follow-up
2 withdrew
24 weeks
4 lost to follow-up
4 withdrew
52 weeks
1 lost to follow-up
8 withdrew
161 assigned to receive CBT
3 not treated
140 adequately treated
18 inadequately treated
160 assigned to receive GET
0 not treated
136 adequately treated
24 inadequately treated
160 assigned to receive SMC
1 not treated
142 adequately treated
17 inadequately treated
2260 excluded
1698 did not meet primary eligibility criteria
1011 no current Oxford diagnosis of CFS
235 physical function score >65
141 trial treatment during present episode
139 unable to comply with protocol
71 contraindication to trial treatment
46 psychiatric exclusion
29 bimodal fatigue score <6
20 aged <18 years
6 unable to speak or read English 
adequately
533 did not meet primary consent criteria
372 patients declined randomisation
115 patients declined to be assessed
46 doctors declined patient’s 
randomisation
29 unrecorded
257 excluded
176 did not meet primary eligibility criteria
67 no current Oxford diagnosis of CFS
52 unable to comply with protocol
16 physical function score >65
13 contraindication to trial treatment
12 psychiatric exclusion
11 trial treatment during present episode
4 bimodal fatigue score <6
1 unable to speak or read English adequately
69 did not meet primary consent criteria
39 patients declined further assessment
28 patients declined randomisation
2 research assessor declined patient’s
randomisation
12 unrecorded
Figure 1: CONSORT trial proﬁ le 
CFS=chronic fatigue syndrome. APT=adaptive pacing therapy. CBT=cognitive behaviour therapy. GET=graded exercise therapy. SMC=specialist medical care alone. 
The numbers of participants per centre ranged from 63 to 135.
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to Likert scoring to more sensitively test our hypotheses of 
eﬀ ectiveness. The two primary outcome measures15,16 are 
valid and reliable and have been used in previous trials.4–7
For safety outcomes, we included non-serious adverse 
events, serious adverse events, serious adverse reactions 
to trial treatments, serious deterioration, and active 
withdrawals from treatment.10 Adverse events were 
deﬁ ned as any clinical change, disease, or disorder 
reported, whether or not related to treatment. Three 
scrutinisers (two physicians and one liaison psychiatrist 
who all specialised in chronic fatigue syndrome) reviewed 
all adverse events and reactions, independently from the 
trial team, and were masked to treatment group, to 
establish whether they were serious adverse events. 
Scrutinisers were then unmasked to treatment allocation 
to establish if any serious adverse events were serious 
adverse reactions. Serious deterioration in health was 
deﬁ ned as any of the following outcomes: a short form-36 
physical function score decrease of 20 or more between 
baseline and any two consecutive assessment interviews;16 
scores of much or very much worse on the participant-
rated clinical global impression change in overall health 
scale at two consecutive assessment interviews;25 
withdrawal from treatment after 8 weeks because of a 
participant feeling worse; or a serious adverse reaction.
For secondary outcomes, we used the clinical global 
impression scale to assess change from baseline in overall 
health.25 This 7-point scale was condensed into three 
categories: negative change (very much worse or much 
worse), minimum change (a little worse, no change, or a 
little better), and positive change (much better or very 
much better). We also assessed overall disability with the 
work and social adjustment scale,26 6-min walking ability 
(distance in m walked),27 Jenkins scale score for disturbed 
sleep,28 hospital anxiety and depression scale score,29 
number of chronic fatigue syndrome symptoms, and 
individual symptoms of postexertional malaise and poor 
concentration or memory, as in the international criteria.12 
These secondary outcomes were a subset of those speciﬁ ed 
in the protocol, selected in the statistical analysis plan as 
most relevant to this report. After participants had been 
told their treatment allocation, but before treatment began, 
they rated how logical their proposed treatment seemed 
and how conﬁ dent they were that it would help them 
(5-point Likert scale with moderately and extremely con-
densed into a positive response to help with interpretation). 
At 52 weeks, participants rated satisfaction with treatment 
received on a 7-point scale, condensed into three categories 
to aid interpretation (satisﬁ ed, neutral, or dissatisﬁ ed).
Statistical analysis
We calculated sample sizes assuming 60% response to 
CBT at 52 weeks, 50% response to GET, 25% response 
to APT, and 10% response to SMC.10 We assumed APT 
to be at least as eﬀ ective as in previous trials of relaxation 
and ﬂ exibility therapies.20,22 For a two-sided test with 
5% signiﬁ cance level and 90% power, we calculated that 
the number of participants needed to compare SMC 
with APT was 135, SMC with GET was 80, and SMC 
with CBT was 40. We increased group size to 150 per 
group to allow for 10% dropout, to provide equality 
between groups, and for secondary analyses. The 
Adaptive pacing 
therapy (n=159)
Cognitive behaviour 
therapy (n=161)
Graded exercise 
therapy (n=160)
Specialist medical 
care alone (n=160)
Overall (n=640)
Demographic data
Age (years) 39 (11) 39 (12) 39 (12) 37 (11) 38 (12)
Female 121 (76%) 129 (80%) 123 (77%) 122 (76%) 495 (77%)
White 146 (92%) 151 (94%) 148 (93%) 150 (94%) 595 (93%)
Any ME group membership 31 (19%) 26 (16%) 25 (16%) 23 (14%) 105 (16%)
Clinical data
International CFS criteria12
As randomised 99 (62%) 100 (62%) 98 (61%) 100 (63%) 397 (62%)
Actual 107 (67%) 106 (66%) 106 (66%) 108 (68%) 427 (67%)
London ME criteria13
As randomised 89 (56%) 90 (56%) 89 (56%) 89 (56%) 357 (56%)
Actual 81 (51%) 84 (52%) 84 (53%) 80 (50%) 329 (51%)
Any depressive disorder
As randomised 55 (35%) 55 (34%) 54 (34%) 55 (34%) 219 (34%)
Actual 54 (34%) 52 (32%) 54 (34%) 53 (33%) 213 (33%)
Any psychiatric disorder* 75 (47%) 75 (47%) 73 (46%) 77 (48%) 300 (47%)
Duration of illness (months) 33 (16–69) 36 (16–104) 35 (18–67) 25 (15–57) 32 (16–68)
Body-mass index (kg/m²) 25·9 (5·5) 25·4 (5·2) 25·5 (4·6) 25·1 (4·5) 25·5 (5·0)
Data are mean (SD), n (%), or median (IQR). ME=myalgic encephalomyelitis. CFS=chronic fatigue syndrome. *Psychiatric disorders included any depressive disorder and any 
anxiety disorder, including phobias, obsessive-compulsive disorder, and post-traumatic stress disorder. 
Table 1: Baseline demographics and clinical characteristics
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statistical analysis plan was ﬁ nalised, including changes 
to the original protocol, and was approved by the trial 
steering committee and the data monitoring and ethics 
committee before outcome data were examined.
We used continuous scores for primary outcomes to 
allow a more straightforward interpretation of the indivi-
dual outcomes, instead of the originally planned 
composite measures (50% change or meeting a 
threshold score).10,30 We prorated primary outcomes 
scales only when there were at most two items per scale 
missing (nine participants for Chalder fatigue question-
naire and 11 for short form-36). Prorating involved 
calculating the mean value of the item scores present 
and replacing the missing values with that score.
We summarised continuous variables with mean (SD) 
or median (IQR) and categorical variables with 
frequencies and proportions. Diﬀ erentiation of 
treatment compared independent ratings of therapy 
sessions with actual treat ment. We calculated the inter-
rater reliability (κ and 95% CI) between the two 
assessors. We used Kruskal-Wallis tests for comparisons 
of therapy received, therapeutic alliance, and manual 
adherence. We compared categorical variables with 
Fisher’s exact test.
A clinically useful diﬀ erence between the means of 
the primary outcomes was deﬁ ned as 0·5 of the SD of 
these measures at baseline,31 equating to 2 points for 
Chalder fatigue questionnaire and 8 points for short 
form-36. A secondary post-hoc analysis compared the 
proportions of participants who had improved between 
baseline and 52 weeks by 2 or more points of the Chalder 
fatigue questionnaire, 8 or more points of the short 
form-36, and improved on both. In another post-hoc 
analysis, we compared the proportions of participants 
who had scores of both primary outcomes within the 
normal range at 52 weeks. This range was deﬁ ned as 
less than the mean plus 1 SD scores of adult attendees 
to UK general practice of 14·2 (+4·6) for fatigue (score 
of 18 or less) and equal to or above the mean minus 1 SD 
scores of the UK working age population of 84 (–24) for 
physical function (score of 60 or more).32,33
We estimated diﬀ erences between treatment groups for 
both primary outcomes with mixed linear regression 
models with Kenward-Roger adjusted standard errors. 
Covariates were treatment group, baseline value of 
outcome, time, and stratiﬁ cation factors (centre, present 
depressive disorder, and alternative criteria for chronic 
fatigue syndrome and myalgic encephalomyelitis; all as 
stratiﬁ ed at entry). Time by treatment interaction terms 
were included to allow extraction of contrasts at 52 weeks. 
Models for the primary outcomes and the clinical global 
impression incorporated random intercepts and slopes 
over time by participant and main health-care practitioner 
(doctor or therapist who saw the participant most 
frequently, or, if equal, the ﬁ rst practitioner to see the 
participant) to allow for clustering of outcomes within 
Adaptive pacing 
therapy (n=159)
Cognitive behaviour 
therapy (n=161)
Graded exercise 
therapy (n=160)
Specialist medical 
care alone (n=160)
p value*
Treatment received
Therapy sessions attended† 13 (12–15) 14 (12–15) 13 (12–14) ·· 0·17
Specialist medical care sessions attended‡ 3 (3–4) 3 (3–4) 3 (3–4) 5 (3–6) 0·0001
Adequate treatment§ 143 (90%) 140 (87%) 136 (85%) 142 (89%) 0·56
Antidepressant at baseline 63 (40%) 57 (35%) 74 (46%) 66 (41%) ··
Antidepressant at 24 weeks¶ 53 (34%) 45 (29%) 61 (40%) 60 (39%) 0·19
Antidepressant at 52 weeks¶ 41 (27%) 47 (31%) 48 (31%) 61 (39%) 0·11
Hypnotic at baseline 6 (4%) 9 (6%) 6 (4%) 5 (3%) ··
Hypnotic at 24 weeks¶ 3 (2%) 7 (5%) 5 (3%) 6 (4%) 0·61
Hypnotic at 52 weeks¶ 5 (3%) 4 (3%) 3 (2%) 7 (5%) 0·62
Non-allocated treatment 8 (5%) 4 (3%) 7 (4%) 22 (14%) 0·0005
Dropouts from treatment 11 (7%) 17 (11%) 10 (6%) 14 (9%) 0·50
Views before treatment
Treatment is logical 134 (84%) 115 (71%) 135 (84%) 79 (49%) <0·0001
Conﬁ dent about treatment 114 (72%) 91 (57%) 112 (70%) 65 (41%) <0·0001
Views after treatment
Satisﬁ ed with treatment¶ 128 (85%) 117 (82%) 126 (88%) 76 (50%) <0·0001
Dissatisﬁ ed with treatment¶ 4 (3%) 7 (5%) 2 (1%) 17 (11%) 0·0010
Therapeutic alliance|| 6·5 (6·0–6·5) 6·5 (5·5–6·8) 6·5 (5·5–7·0) ·· 0·96
Adherence to manual** 6·0 (6·0–6·5) 6·0 (5·0–6·5) 6·5 (6·0–6·5) ·· 0·35
Data are median (IQR) or n (%). *p values across all groups. †86% of sessions were received face-to-face and 14% by telephone. ‡94% of sessions were received face-to-face 
and 6% by telephone. §Adequate treatment was ten or more sessions of therapy or three or more sessions of specialist medical care alone. ¶Percentages exclude missing 
data. ||Scored 1–7 (1=poor, 7=excellent). **Scored 1–7 (1=not at all, 7=very much so).
Table 2: Treatment details
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practitioner. We calculated intraclass correlation 
coeﬃ  cients, adjusted for baseline outcomes, using one-
way random eﬀ ects analysis of covariance at 52 weeks 
within every treatment group. Unadjusted and Bonferroni 
corrected p values are provided for ﬁ ve comparisons for 
both primary outcomes. Comparisons of primary 
outcomes across treatment groups by alternative criteria 
for chronic fatigue syndrome and myalgic encepha-
lomyelitis, and comorbid depressive disorder included 
the treatment by criteria or disorder interaction terms. 
Because some errors were made in stratiﬁ cation at 
randomisation, we used true status variables rather than 
status at stratiﬁ cation as covariates.
We calculated adverse event and reaction rates by 
dividing the number of events by person-years of 
follow-up multiplied by 100, and compared rate 
diﬀ erences (95% CI) between treatment groups.
We analysed changes in clinical global impression 
scale using binary logistic generalised estimating 
equations regression with an exchangeable working 
correlation and bootstrapped standard errors. We 
analysed the number of chronic fatigue syndrome 
symptoms with ordinary least squares linear regression, 
and the presence of speciﬁ c chronic fatigue syndrome 
symptoms with logistic regression. We analysed 
secondary outcomes with mixed linear regression 
models with random participant intercepts and slopes 
over time, apart from the walking test, which had 
random intercepts only. Covariates in the models were 
otherwise the same, except for clinical global impression 
(not measured at baseline) and chronic fatigue syndrome 
symptoms (measured only at 52 weeks).
We excluded participants from the intention-to-treat 
population for whom we had no primary outcome data 
in the ﬁ nal analysis, which used restricted maximum 
likelihood. The per-protocol analysis excluded 
participants who were ineligible after randomisation, 
treated at a second centre, or did not received adequate 
treatment, adjusting for actual stratiﬁ cation factors. 
Statistical analyses were done with Stata version 10, 
SAS version 9.1, and SPSS version 18.
This trial is registered at http://isrctn.org, number 
ISRCTN54285094.
Role of the funding source
The sponsors of the study had no role in study design, 
data collection, data analysis, data interpretation, or 
writing of the report. All named authors had access to the 
data, commented on drafts, and approved the ﬁ nal report. 
Members of the writing group had responsibility for 
submitting the report, and PDW had ﬁ nal responsibility 
for the decision to submit for publication.
Results
Figure 1 shows the trial proﬁ le. Brieﬂ y, 898 (28%) of 
3158 patients screened for eligibility progressed to 
baseline screening and 641 (71%) participants were 
recruited (ﬁ gure 1). The commonest reason for exclu-
sion from initial clinician screening was failure to meet 
Oxford criteria for chronic fatigue syndrome 
(1011 participants). 745 (74%) of these excluded patients 
did not have chronic fatigue syndrome and the rest did 
not meet Oxford criteria despite having clinician-
diagnosed chronic fatigue syndrome. Table 1 shows 
Fatigue* Physical function†
Adaptive pacing 
therapy
Cognitive 
behaviour therapy
Graded exercise 
therapy
Specialist medical 
care alone
Adaptive pacing 
therapy
Cognitive 
behaviour therapy
Graded exercise 
therapy
Specialist medical 
care alone
Baseline 28·5 (4·0); n=159 27·7 (3·7); n=161 28·2 (3·8); n=160 28·3 (3·6); n=160 37·2 (16·9); n=159 39·0 (15·3); n=161 36·7 (15·4); n=160 39·2 (15·4); n=160
12 weeks 24·2 (6·4); n=153 23·6 (6·5); n=153 22·8 (7·5); n=153 24·3 (6·5); n=154 41·7 (19·9); n=153 51·0 (20·7); n=153 48·1 (21·6); n=153 46·6 (20·4); n=154
24 weeks 23·7 (6·9); n=155 21·5 (7·8); n=148 21·7 (7·1); n=150 24·0 (6·9); n=152 43·2 (21·4); n=155 54·2 (21·6); n=148 55·4 (23·3); n=150 48·4 (23·1); n=152
52 weeks 23·1 (7·3); n=153 20·3 (8·0); n=148 20·6 (7·5); n=154 23·8 (6·6); n=152 45·9 (24·9); n=153 58·2 (24·1); n=148 57·7 (26·5); n=154 50·8 (24·7); n=152
Mean diﬀ erence (95% CI) 
from SMC (52 weeks)
–0·7 (–2·3 to 0·9) –3·4 (–5·0 to –1·8) –3·2 (–4·8 to –1·7) ·· –3·4 (–8·4 to 1·6) 7·1 (2·0 to 12·1) 9·4 (4·4 to 14·4) ··
Unadjusted p values 0·38 0·0001 0·0003 ·· 0·18 0·0068 0·0005 ··
Bonferroni adjusted 
p values
0·99 0·0006 0·0013 ·· 0·89 0·0342 0·0025 ··
Mean diﬀ erence (95% CI) 
from APT (52 weeks)
·· –2·7 (–4·4 to –1·1) –2·5 (–4·2 to –0·9) ·· ·· 10·5 (5·4 to 15·6) 12·8 (7·7 to 17·9) ··
Unadjusted p values ·· 0·0027 0·0059 ·· ·· 0·0002 <0·0001 ··
Bonferroni adjusted 
p values
·· 0·0136 0·0294 ·· ·· 0·0012 0·0002 ··
Number improved from 
baseline‡
99 (65%) 113 (76%) 123 (80%) 98 (65%) 75 (49%) 105 (71%) 108 (70%) 88 (58%)
Data are mean scores (SD) or n (%), unless otherwise stated. Comparisons of diﬀ erences across groups made at 52 weeks are from the ﬁ nal adjusted models, so are slightly diﬀ erent from unadjusted values. 
p values for comparisons are unadjusted, with Bonferroni values adjusted for ﬁ ve comparisons for every primary outcome. *Chalder fatigue questionnaire (range 0–33, 0=best).15 †Short form-36 physical 
function subscale score (range 0–100, 100=best).16 ‡Participants improved from baseline by two or more points for fatigue and eight or more for physical function.
Table 3: Primary outcomes of fatigue and physical function
Articles
830 www.thelancet.com   Vol 377   March 5, 2011
baseline characteristics of participants, which were 
much the same between groups, apart from a shorter 
duration of illness in the SMC group than was noted in 
the other groups. 33 (5%) of 640 participants were lost to 
follow-up, but rates did not diﬀ er between groups 
(p=0·30; ﬁ gure 1). Ten of these 33 participants had no 
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Figure 2: Physical function subscale and fatigue questionnaire scores by treatment group
Data are unadjusted means (95% CI). pinteraction is the p-value of the interaction between treatment and criteria or disorder from the adjusted model. CFS=chronic 
fatigue syndrome. ME=myalgic encephalomyelitis. (A–D) Lowest fatigue score is best. (E–H) Highest physical function score is best. 
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outcome data, and were therefore excluded from the 
ﬁ nal analysis. Primary outcomes were assessed at the 
time of dropout for three participants and included in 
the ﬁ nal analyses. Research assessors recorded primary 
outcomes (eg, dictated over the telephone) on 74 (4%) of 
1920 occasions.
Table 2 shows details of treatments received. Participants 
allocated to SMC alone received more sessions, but there 
were no diﬀ erences in the number of SMC sessions or 
therapy sessions received between the other three groups. 
There were no diﬀ erences between groups in the 
proportions who had received adequate treatment (85% or 
more in every group). Participants’ expectations were 
high for APT and GET, but lower for CBT and SMC 
(table 2). Most of those who received a therapy were 
satisﬁ ed with treatment (82% or more for the three 
therapies), but fewer were satisﬁ ed with SMC (50%). 
Number of treatment dropouts did not diﬀ er between 
groups (p=0·50; table 2). The two independent therapy 
assessors rated 58 (94%) of 62 and 57 (92%) of 62 therapy 
sessions as being the one allocated; only one (2%) session 
was rated by both assessors as diﬀ erent from that 
allocated. The inter-rater reliability (κ; 95% CI) was 0·86 
(0·75–0·97). The independent assessors were unmasked 
in 25 (40%) of 62 sessions that they listened to. All three 
therapies were rated as adhering well to the manuals. 
Thera peutic alliance median scores were high and the 
same across therapies.
Table 3 shows baseline and outcomes data, and ﬁ gure 2 
shows proﬁ les for the primary outcomes. In the ﬁ nal-
adjusted models (ﬁ gure 3), participants had less fatigue 
and better physical function after CBT and GET than they 
did after APT or SMC alone. Outcomes after APT were 
no better than they were after SMC. Allowing for 
clustering eﬀ ects caused by participants attending the 
same main practitioner had little eﬀ ect on these results; 
intraclass correlation coeﬃ  cients ranged from –0·02 to 
0·11 for fatigue, and –0·01 to 0·03 for physical function. 
Participant subgroups meeting international criteria for 
chronic fatigue syndrome, London criteria for myalgic 
encephalomyelitis, and depressive disorder criteria did 
not diﬀ er in the pattern of treatment eﬀ ects (ﬁ gure 2; all 
pinteractions were non-signiﬁ cant).
64 (42%) of 153 participants in the APT group improved 
by at least 2 points for fatigue and at least 8 points for 
physical function at 52 weeks, compared with 87 (59%) of 
148 participants for CBT, 94 (61%) of 154 participants for 
GET, and 68 (45%) of 152 participants for SMC. More 
participants improved after CBT compared with APT 
(p=0·0033) or SMC (p=0·0149), and more improved with 
GET compared with APT (p=0·0008) or SMC (p=0·0043); 
APT did not diﬀ er from SMC (p=0·61; webappendix p 2).
25 (16%) of 153 participants in the APT group were 
within normal ranges for both primary outcomes at 
52 weeks, compared with 44 (30%) of 148 participants for 
CBT, 43 (28%) of 154 participants for GET, and 22 (15%) 
of 152 participants for SMC. More participants were 
within normal ranges after CBT than APT (p=0·0057) or 
SMC (p=0·0014), and more were within normal ranges 
with GET compared with APT (p=0·0145) or SMC 
(p=0·0040); APT did not diﬀ er from SMC (p=0·65).
Webappendix p 3 shows the per-protocol analysis. 
Diﬀ erences between treatments were very similar to 
those of the ﬁ nal analysis, but magnitude was almost 
always higher in the per-protocol analysis.
Table 4 shows safety outcomes. Non-serious adverse 
events were common. Participants who received CBT 
reported slightly fewer such events than did those in the 
APT (p=0·0081) and SMC (p=0·0016) groups. Serious 
adverse events and serious deterioration were uncommon; 
serious adverse reactions were rare. There were more 
serious adverse events in the GET group than there were 
in the SMC group (p=0·0433). Rates of serious adverse 
reactions and serious deterioration did not diﬀ er between 
treatment groups. Webappendix pp 4–5 shows a summary 
of serious adverse events and serious adverse reactions.
Table 5 shows data for the clinical global impression 
scale ratings. At 52 weeks, more patients rated themselves 
as much better or very much better in overall health after 
CBT and GET than did after APT and SMC. A minority 
(≤9% in every group) rated themselves as much worse or 
very much worse, which did not diﬀ er between groups.
Table 6 shows other secondary outcomes. At 52 weeks, 
participants in the CBT and GET groups had better 
-6 -4 -2 0 2
Fatigue mean diﬀerence (95% CI)
APT vs SMC
CBT vs SMC
GET vs SMC
CBT vs APT
GET vs APT
APT vs SMC
CBT vs SMC
GET vs SMC
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GET vs APT
-12 -8 -4 0 4 8 12 16 20
Physical function mean diﬀerence (95% CI)
A
B
Figure 3: Primary outcome treatment diﬀ erences for fatigue (A) and physical 
function (B) at 52 weeks
(A) Negative values for fatigue favour the ﬁ rst treatment group in each pair of 
comparisons. (B) Positive values for physical function favour the ﬁ rst treatment 
group in each pair of comparisons. APT=adaptive pacing therapy. SMC=specialist 
medical care. CBT=cognitive behaviour therapy. GET=graded exercise therapy.
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outcomes than did participants in the APT and SMC groups 
for work and social adjustment scores, sleep disturbance, 
and depression (with the one exception that GET was no 
diﬀ erent from APT for depression). Anxiety was lower after 
CBT and GET than it was after SMC, but not than after 
APT. There were fewer chronic fatigue syndrome symptoms 
after CBT than there were after SMC. Poor concentration 
and memory did not diﬀ er between groups. Postexertional 
malaise was lower after CBT and GET than it was after APT 
and SMC. 6-min walking distances were greater after GET 
than they were APT and SMC, but were no diﬀ erent after 
CBT compared with APT and SMC. There were no 
 Adaptive pacing 
therapy (n=159)
Cognitive behaviour 
therapy (n=161)
Graded exercise 
therapy (n=160)
Specialist medical care 
alone (n=160)
Non-serious adverse events 949 848 992 977
Participants with non-serious adverse events 152 (96%) 143 (89%) 149 (93%) 149 (93%)
Non-serious adverse events per 100 person-years 597 (559–636) 527 (492–563) 620 (582–660) 611 (573–650)
Serious adverse events 16 8 17 7
Participants with serious adverse events 15 (9%) 7 (4%) 13 (8%) 7 (4%)
Serious adverse events per 100 person-years 10·1 (5·8–16·3) 5·0 (2·2–9·8) 10·6 (6·2–17·0) 4·4 (1·8–9·0)
Serious adverse reactions 2 4 2 2
Participants with serious adverse reactions 2 (1%) 3 (2%) 2 (1%) 2 (1%)
Serious adverse reactions per 100 person-years 1·3 (0·2–4·5) 2·5 (0·7–6·4) 1·3 (0·2–4·5) 1·3 (0·2–4·5)
Serious deterioration (composite)* 13 (8%) 14 (9%) 10 (6%) 15 (9%)
Physical functioning reduction 7 (4%) 5 (3%) 5 (3%) 6 (4%)
PCGI worse 5 (3%) 7 (4%) 1 (<1%) 10 (6%)
Withdrawn due to worsening 3 (2%) 0 2 (1%) 1 (<1%)
Serious adverse reactions 2 (1%) 3 (2%) 2 (1%) 2 (1%)
Diﬀ erences in serious deterioration
Comparison with specialist medical care –1·2%; p=0·71 –0·7%; p=0·83 –3·1%; p=0·30 ··
Comparison with adaptive pacing therapy ·· 0·5%; p=0·87 –1·9%; p=0·51 ··
Data are n, n (%), or rate (95% CI), unless otherwise stated. Adverse events were considered serious when they involved death, hospital admission, increased severe and 
persistent disability, self-harm, were life-threatening, or required an intervention to prevent one of these. There were no suspected unexpected serious adverse reactions. 
PCGI=participant-rated clinical global impression. *Serious deterioration composite is either of a short form-36 physical function subscale score reduction at two consecutive 
visits, a PCGI score of much worse or very much worse at two consecutive visits, withdrawal from treatment due to explicit worsening, or a serious adverse reaction; the 
numbers withdrawn from treatment due to worsening is a subset of all those withdrawing from treatment shown in table 2.
Table 4: Safety outcomes
Adaptive pacing 
therapy (n=159)
Cognitive behaviour 
therapy (n=161)
Graded exercise therapy 
(n=160)
Specialist medical 
care alone (n=160)
Change from baseline
12 weeks 153 (96%) 153 (95%) 151 (94%) 151 (94%)
Positive change 20 (13%) 32 (21%) 37 (25%) 7 (5%)
Minimum change 126 (82%) 113 (74%) 111 (74%) 133 (88%)
Negative change 7 (5%) 8 (5%) 3 (2%) 11 (7%)
24 weeks 155 (97%) 149 (93%) 148 (93%) 151 (94%)
Positive change 37 (24%) 56 (38%) 54 (37%) 28 (19%)
Minimum change 111 (72%) 82 (55%) 89 (60%) 107 (71%)
Negative change 7 (5%) 11 (7%) 5 (3%) 16 (11%)
52 weeks 153 (96%) 147 (91%) 152 (95%) 152 (95%)
Positive change 47 (31%) 61 (41%) 62 (41%) 38 (25%)
Minimum change 96 (63%) 77 (52%) 80 (53%) 100 (66%)
Negative change 10 (7%) 9 (6%) 10 (7%) 14 (9%)
Odds ratio (positive change vs negative or minimum changes)
Compared with specialist medical care 1·3 (0·8–2·1); p=0·31 2·2 (1·2–3·9); p=0·011 2·0 (1·2–3·5); p=0·013 ··
Compared with adaptive pacing therapy ·· 1·7 (1·0–2·7); p=0·034 1·5 (1·0–2·3); p=0·028 ··
Data are n (%) or odds ratio (95% CI). Comparisons made at 52 weeks were taken from the ﬁ nal adjusted models. Positive change was deﬁ ned as very much better or much 
better. Minimum change was deﬁ ned as a little better, no change, or a little worse. Negative change was deﬁ ned as much worse or very much worse.
Table 5: Participant-rated clinical global impression of change in overall health
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diﬀ erences in any secondary outcomes between APT and 
SMC groups (webappendix pp 6–9).
Discussion
When added to SMC, CBT and GET had greater success 
in reducing fatigue and improving physical function than 
did APT or SMC alone. APT was no better than was SMC 
alone. Our ﬁ ndings were much the same for participants 
meeting the diﬀ erent diagnostic criteria for chronic 
fatigue syndrome and for myalgic encephalomyelitis, for 
those with depressive disorder, and after allowing for 
clustering eﬀ ects. Other secondary outcomes showed a 
very similar pattern. There were no important diﬀ erences 
in safety outcomes between treatment options.
Adaptive pacing therapy 
(n=159)
Cognitive behaviour 
therapy (n=161)
Graded exercise therapy 
(n=160)
Specialist medical care 
alone (n=160)
Work and social adjustment scale 150 (94%) 143 (89%) 144 (90%) 151 (94%)
Baseline score 27·9 (6·1) 27·4 (6·2) 27·3 (6·3) 26·9 (6·7)
52-week score 24·5 (8·8) 21·0 (9·6) 20·5 (9·4) 23·9 (9·2)
Comparison with SMC 0·1; p=0·93 –3·6; p=0·0001 –3·2; p=0·0006 ··
Comparison with APT ·· –3·7; p=0·0001 –3·3; p=0·0004 ··
6-min walking test 111 (70%) 123 (76%) 110 (69%) 118 (74%)
Baseline distance (m) 314 (90) 333 (86) 312 (87) 326 (95)
52-week distance (m) 334 (117) 354 (106) 379 (100) 348 (108)
Comparison with SMC –5·7; p=0·55 –1·5; p=0·87 35·3; p=0·0002 ··
Comparison with APT ·· 4·2; p=0·65 41·0; p<0·0001 ··
Jenkins sleep scale 150 (94%) 143 (89%) 144 (90%) 151 (94%)
Baseline score 12·1 (4·9) 12·5 (4·9) 11·7 (4·3) 12·4 (5·0)
52-week score 10·6 (4·8) 9·9 (5·3) 9·0 (4·8) 11·0 (5·0)
Comparison with SMC –0·1; p=0·76 –1·1; p=0·0216 –1·4; p=0·0024 ··
Comparison with APT ·· –0·9; p=0·0466 –1·3; p=0·0062 ··
HADS depression scale 149 (94%) 143 (89%) 144 (90%) 151 (94%)
Baseline score 8·1 (3·9) 8·3 (3·7) 8·2 (3·6) 8·0 (3·9)
52-week score 7·2 (4·5) 6·2 (3·7) 6·1 (4·1) 7·2 (4·7)
Comparison with SMC –0·6; p=0·11 –1·4; p=0·0003 –1·1; p=0·0035 ··
Comparison with APT ·· –0·8; p=0·0382 –0·5; p=0·18 ··
HADS anxiety scale 149 (94%) 143 (89%) 144 (90%) 149 (93%)
Baseline score 8·1 (4·2) 8·1 (4·3) 8·0 (4·2) 7·9 (4·3)
52-week score 7·5 (4·2) 6·8 (4·2) 7·1 (4·5) 8·0 (4·4)
Comparison with SMC –0·7; p=0·0713 –1·4; p=0·0003 –1·0; p=0·0142 ··
Comparison with APT ·· –0·7; p=0·0671 –0·3; p=0·50 ··
Chronic fatigue syndrome symptom count 151 (95%) 145 (90%) 144 (90%) 149 (93%)
Baseline 4·8 (1·8) 4·6 (1·8) 4·6 (1·8) 4·7 (1·7)
52 week 3·8 (2·3) 3·4 (2·3) 3·4 (2·5) 3·9 (2·2)
Comparison with SMC –0·1; p=0·62 –0·5; p=0·0329 –0·4; p=0·0916 ··
Comparison with APT ·· –0·4; p=0·0986 –0·3; p=0·23 ··
Poor concentration or memory 151 (95%) 145 (90%) 144 (90%) 149 (93%)
Baseline (n [%] with symptoms) 122 (77%) 117 (73%) 122 (76%) 115 (72%)
52 weeks (n [%] with symptoms) 93 (59%) 73 (45%) 76 (48%) 90 (56%)
Comparison with SMC Odds ratio 1·0; p=0·97 Odds ratio 0·6; p=0·0602 Odds ratio 0·7; p=0·14 ··
Comparison with APT ·· Odds ratio 0·6; p=0·0629 Odds ratio 0·7; p=0·15 ··
Postexertional malaise 151 (95%) 145 (90%) 144 (90%) 149 (93%)
Baseline (n [%] with symptoms) 134 (84%) 135 (84%) 131 (82%) 139 (87%)
52 weeks (n [%] with symptoms) 100 (63%) 79 (49%) 71 (44%) 101 (63%)
Comparison with SMC Odds ratio 1·0; p=0·86 Odds ratio 0·6; p=0·0254 Odds ratio 0·5; p=0·0026 ··
Comparison with APT ·· Odds ratio 0·6; p=0·0380 Odds ratio 0·5; p=0·0042 ··
Data are number of completed questionnaires at 52 weeks (%), means (SD), or mean diﬀ erence, unless otherwise stated. Comparisons across treatment arms at 52 weeks are from 
the ﬁ nal adjusted models. Webappendix pp 6–9 shows forest plots of mean diﬀ erences (95% CI) and odds ratios (95% CI) for comparisons between groups. APT=adaptive pacing 
therapy. SMC=specialist medical care alone. HADS=hospital anxiety and depression scale.
Table 6: Secondary outcomes
Articles
834 www.thelancet.com   Vol 377   March 5, 2011
Mean diﬀ erences between groups on primary 
outcomes almost always exceeded predeﬁ ned clinically 
useful diﬀ erences for CBT and GET when compared 
with APT and SMC. In all comparisons of the proportions 
of participants who had either improved or were within 
normal ranges for these outcomes, CBT and GET did 
better than did APT or SMC alone. No more than 30% of 
participants were within normal ranges for both 
outcomes and only 41% rated themselves as much better 
or very much better in their overall health. We suggest 
that these ﬁ ndings show that either CBT or GET, when 
added to SMC, is an eﬀ ective treatment for chronic 
fatigue syndrome, and that the size of this eﬀ ect is 
moderate (panel 2).
Our conclusions are supported by secondary outcomes, 
as both CBT and GET provided greater improvements 
than did APT and SMC for most outcomes. The objective 
walking test favoured GET over CBT, whereas CBT 
provided the largest reduction in depression. The 
comparatively greater reduction in postexertional 
malaise with both CBT and GET compared with the 
other two treatments is notable, since the risk of 
exacerbation of this symptom is commonly given as a 
reason to avoid treatments such as GET. The 47% 
prevalence of mood and anxiety disorders at baseline 
was much the same as that noted in previous trials in 
secondary care (38–56%).20,23,36 The equivalent use of 
antidepressants in the treatment groups implies that 
the diﬀ erences in outcomes are unlikely to be attributable 
to these drugs.
There were no diﬀ erences between groups in the 
proportions with serious deterioration or serious adverse 
reactions. The increased rate of serious adverse events 
with GET compared with SMC is unlikely to be important 
because serious adverse events were not thought by the 
independent scrutinisers to be related to treatment. 
Consequently, if these treatments are delivered as 
described, by similarly qualiﬁ ed and trained clinicians, 
patients need not be concerned about safety.37
The ﬁ nding that APT when added to SMC was no more 
eﬀ ective than SMC alone was contrary to our initial 
hypothesis. This ﬁ nding might in part be caused by greater 
improvement after SMC than was expected. Suboptimum 
delivery of APT is an unlikely explanation because APT 
therapists were the most experienced; the therapeutic 
alliance and the adherence to manuals were rated highly 
in this group and participant satisfaction did not diﬀ er 
from that for other therapies. Since participants’ conﬁ dence 
that APT would help them was much the same as for GET, 
and greater than that for CBT, they were unlikely to have 
been biased by negative expectations. The fundamental 
diﬀ erence between APT and both CBT and GET is that 
APT encourages adaptation to the illness,13,17,18 whereas 
CBT and GET encourage gradual increases in activity with 
the aim of ameliorating the illness.2,4,7 Our results do not 
support pacing, in the form of APT, as a ﬁ rst-line therapy 
for chronic fatigue syndrome.
We plan to report relative cost-eﬀ ectiveness of the 
treatments, their moderators and mediators, whether 
subgroups respond diﬀ erently, and long-term follow-up 
in future publications. Our ﬁ nding that studied 
treatments were only moderately eﬀ ective also suggests 
research into more eﬀ ective treatments is needed. The 
eﬀ ectiveness of behavioural treatments does not imply 
that the condition is psychological in nature.
Our ﬁ ndings were strengthened by the small numbers 
of dropouts, high rates of acceptance of the treatments, 
use of manual-deﬁ ned treatments provided by competent 
clinicians, high rates of participant satisfaction, adherence 
to manuals, and therapeutic alliance. The PACE ﬁ ndings 
can be generalised to patients who also meet alternative 
diagnostic criteria for chronic fatigue syndrome12 and 
myalgic encephalomyelitis13 but only if fatigue is their 
main symptom.11 
Our trial had limitations. We excluded patients unable 
to attend hospital. Our results apply to patients referred 
to secondary care. SMC is not the same as usual medical 
care that might be provided by a family doctor; this study 
Panel 2: Research in context
Systematic review
We searched the PubMed and Cochrane Library databases up to 
Nov 6, 2010, without language restrictions for full papers 
reporting randomised controlled trials, systematic reviews, and 
meta-analyses with the search terms “chronic fatigue 
syndrome”, “myalgic encephalomyelitis”, “myalgic 
encephalopathy “ and “cognitive behaviour therapy”, “exercise”, 
“pacing”. We excluded trials of adolescents, education, and 
group interventions. Our search identiﬁ ed the two most recent 
systematic reviews,4,5 two meta-analyses,6,7 and two additional 
trials34,35 that were not included in these reviews. The reviews 
and meta-analyses concluded that cognitive behaviour therapy 
and graded exercise therapy are moderately eﬀ ective 
treatments for chronic fatigue syndrome, and that limitations 
of previous trials included small size, an absence of data for 
safety outcomes, and high dropout rates.4–7 The ﬁ ndings from 
these studies concur with the UK National Institute for Health 
and Clinical Excellence guidelines.2
Interpretation
In the pacing, graded activity, and cognitive behaviour therapy: 
a randomised evaluation (PACE) trial, we aﬃ  rm that cognitive 
behaviour therapy and graded exercise therapy are moderately 
eﬀ ective outpatient treatments for chronic fatigue syndrome 
when added to specialist medical care, as compared with 
adaptive pacing therapy or specialist medical care alone. 
Findings from PACE also allow the following interpretations: 
adaptive pacing therapy added to specialist medical care is no 
more eﬀ ective than specialist medical care alone; our ﬁ ndings 
apply to patients with diﬀ erently deﬁ ned chronic fatigue 
syndrome and myalgic encephalomyelitis whose main 
symptom is fatigue; and all four treatments tested are safe. 
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was not designed to compare SMC with usual medical 
care. Although more than 3000 patients attending 
clinics had to be screened to identify the 641 recruited, 
the commonest reason for exclusion at screening was 
not having chronic fatigue syndrome. We chose 
conventional criteria for deﬁ ning clinically useful 
diﬀ erences between treatments, although other 
thresholds could have been chosen.32 SMC was not as 
closely monitored or supervised as the other therapies, 
and participants receiving SMC alone had more sessions 
than did those in the therapy groups; this is unlikely to 
have aﬀ ected comparisons between the groups. Masking 
of participants or clinicians to treatment allocation was 
not possible, and research assessors were also not 
masked. Primary outcomes were subjective and rated by 
participants. While this avoided investigator bias, it 
could be subject to other biases. Although participant-
rated outcome measures could have been aﬀ ected by 
expectations of treatment, which were highest for APT 
and GET, CBT was one of the two most eﬀ ective 
treatments despite lower expectations.
Findings from the PACE trial suggest that individually 
delivered CBT and GET, when added to SMC, are more 
eﬀ ective and as safe as APT added to SMC or SMC alone. 
Patients attending secondary care with chronic fatigue 
syndrome should be oﬀ ered individual CBT or GET, 
alongside SMC.
PACE trial group
Trial Steering Committee (independent members)—Janet Darbyshire 
(Chair), Jenny Butler, Patrick Doherty, Stella Law, M Llewelyn, and 
Tom Sensky. Observers—Sir Mansel Aylward (Department for Work and 
Pensions, London, UK), Sir Peter Spencer and Chris Clark (Action for 
ME, Bristol, UK), Stephen Stansfeld (Queen Mary University of London, 
London, UK), Alison Wearden (Fatigue Intervention by Nurses 
Evaluation trial), and members of analysis strategy group and writing 
and publication oversight committee. Data Monitoring and Ethics 
Committee—Paul Dieppe (initial Chair), Astrid Fletcher (ﬁ nal Chair), 
and Charlotte Feinmann. Independent assessors of the trial safety data—
Hiroko Akagi, Alastair Miller, and Gavin Spickett. Independent assessors of 
therapy—Barbara Bowman and Deborah Fleetwood.
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